Takeda Oncology
Anette Nilsson is an experienced professional in market access and reimbursement, currently serving as National Market Access Manager at Takeda Oncology since March 2019. Previously, Anette has held significant roles including Regional Market Access Manager at Bayer Pharmaceuticals, Nordic Reimbursement & Market Access Manager at Allergan, and Senior Market Access Manager at Lilly, among others. Anette’s expertise includes establishing strong relationships with payers, securing optimal reimbursement, and identifying new business opportunities across the pharmaceutical industry. Anette has a solid background in economic planning and budget management, complemented by a Bachelor of Science degree in Public Administration from Lund University.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.